Prospective Grant of Exclusive Commercialization License: The Use of Cysteamine for the Treatment of Pancreatic Cancer, Breast Cancer and Hepatocellular Cancer, 59708-59709 [2013-23528]
Download as PDF
59708
Federal Register / Vol. 78, No. 188 / Friday, September 27, 2013 / Notices
Room 3266, Bethesda, MD 20892–7616, 301–
451–2634, maja.maric@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Peer Review Meeting.
Date: October 28–29, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Sheraton—Silver Spring, Cedar
Room, 8777 Georgia Avenue, Silver Spring,
MD 20910.
Contact Person: Maryam Feili-Hariri,
Ph.D., Scientific Review Officer, Scientific
Review Program, DHHS/NIH/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892, 301–594–3243, haririmf@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Contact Person: Victor Henriquez, Ph.D.,
Scientific Review Officer, DEA/SRB/NIDCR,
6701 Democracy Blvd., Room 668, Bethesda,
MD 20892–4878, 301–451–2405, henriquv@
nidcr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: September 23, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–23527 Filed 9–26–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2013–23526 Filed 9–26–13; 8:45 am]
Prospective Grant of Exclusive
Commercialization License: The Use of
Cysteamine for the Treatment of
Pancreatic Cancer, Breast Cancer and
Hepatocellular Cancer
BILLING CODE 4140–01–P
AGENCY:
Dated: September 23, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health,
HHS.
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Dental and
Craniofacial Research; Notice of
Closed Meeting
pmangrum on DSK3VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel; Clinical Trial or Biomarker
Clinical Evaluation Study Planning Grant
and Clinical Trial Implementation or
Biomarker Clinical Evaluation Study
Cooperative Agreement Applications Review
Panel.
Date: October 21, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 701, 6707 Democracy
Boulevard, Bethesda, MD 20892.
14:21 Sep 26, 2013
Jkt 229001
This notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
indicates that the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive commercialization
license to practice the inventions
embodied in technology family E–219–
2013/0, including U.S. patent
application 61/814,010 entitled ‘‘A
Novel Role of Cysteamine in
Suppression of Cancer Invasion and
Metastasis and Prolonging Survival of
Host Through Inhibition of Matrix
Metalloproteinases in Human Cancer’’
[HHS Ref. E–219–2013/0–US–01],
Canadian patent application 2,813,514
entitled ‘‘Use of Cysteamine and
Derivatives Thereof to Suppress Tumor
Metastases’’ [HHS Ref. E–219–2013/0–
CA–02], South Korean patent
application 10–2013–43713 entitled
‘‘Use of Cysteamine and Derivatives
Thereof to Suppress Tumor
Metastases’’[HHS Ref. E–219–2013/0–
KR–03], Australian patent application
2013205350 entitled ‘‘Use of
Cysteamine and Derivatives Thereof to
Suppress Tumor Metastases’’ [HHS Ref.
E–219–2013/0–AU–04], and Mexican
patent application MX/a/2013/004423
entitled ‘‘Use of Cysteamine and
Derivatives Thereof to Suppress Tumor
Metastases’’ [HHS Ref. E–219–2013/0–
MX–05]; and all related continuing and
foreign patents/patent applications for
these technology families, to Raptor
Pharmaceuticals, Inc. The patent rights
SUMMARY:
National Institutes of Health
VerDate Mar<15>2010
Notice.
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
in these inventions have been assigned
to and/or exclusively licensed to the
Government of the United States of
America.
The prospective exclusive
commercialization license territory may
be worldwide, and the field of use may
be limited to:
The treatment of pancreatic cancer,
breast cancer and hepatocellular
carcinoma (HCC) by using compositions
containing cysteamine.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
October 28, 2013 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive
commercialization license should be
directed to: David A. Lambertson, Ph.D.,
Senior Licensing and Patenting
Manager, Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–4632; Facsimile: (301) 402–
0220; Email: lambertsond@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Cysteamine is a naturally occurring
degradation product of the amino acid
cysteine that is most commonly used for
the treatment of cystinosis. The
inventors on this technology have
demonstrated that cysteamine
suppresses the activity of matrix
metalloproteinases (MMPs), enzymes
that have been implicated in tumor
invasion and metastasis. Importantly,
administration of cysteamine was able
to reduce invasion and metastasis in
mouse xenograft tumor models for
pancreatic cancer, prolonging the
survival of the mice while having no
adverse side effects. Based on these
findings, cysteamine could represent a
novel therapeutic treatment of cancer
with fewer side-effects than current
therapies.
The prospective exclusive
commercialization license will comply
with the terms and conditions of 35
U.S.C. 209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless the NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404
within thirty (30) days from the date of
this published notice.
Complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
license. Comments and objections
E:\FR\FM\27SEN1.SGM
27SEN1
Federal Register / Vol. 78, No. 188 / Friday, September 27, 2013 / Notices
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: September 20, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
& Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–23528 Filed 9–26–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5681–N–39]
Federal Property Suitable as Facilities
To Assist the Homeless
Office of the Assistant
Secretary for Community Planning and
Development, HUD.
ACTION: Notice.
AGENCY:
This Notice identifies
unutilized, underutilized, excess, and
surplus Federal property reviewed by
HUD for suitability for use to assist the
homeless.
FOR FURTHER INFORMATION CONTACT:
Juanita Perry, Department of Housing
and Urban Development, 451 Seventh
Street SW., Room 7266, Washington, DC
20410; telephone (202) 402–3970; TTY
number for the hearing- and speechimpaired (202) 708–2565 (these
telephone numbers are not toll-free), or
call the toll-free Title V information line
at 800–927–7588.
SUPPLEMENTARY INFORMATION: In
accordance with 24 CFR part 581 and
section 501 of the Stewart B. McKinney
Homeless Assistance Act (42 U.S.C.
11411), as amended, HUD is publishing
this Notice to identify Federal buildings
and other real property that HUD has
reviewed for suitability for use to assist
the homeless. The properties were
reviewed using information provided to
HUD by Federal landholding agencies
regarding unutilized and underutilized
buildings and real property controlled
by such agencies or by GSA regarding
its inventory of excess or surplus
Federal property. This Notice is also
published in order to comply with the
December 12, 1988 Court Order in
National Coalition for the Homeless v.
Veterans Administration, No. 88–2503–
OG (D.D.C.).
Properties reviewed are listed in this
Notice according to the following
categories: Suitable/available, suitable/
unavailable, and suitable/to be excess,
and unsuitable. The properties listed in
the three suitable categories have been
pmangrum on DSK3VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
14:21 Sep 26, 2013
Jkt 229001
reviewed by the landholding agencies,
and each agency has transmitted to
HUD: (1) Its intention to make the
property available for use to assist the
homeless, (2) its intention to declare the
property excess to the agency’s needs, or
(3) a statement of the reasons that the
property cannot be declared excess or
made available for use as facilities to
assist the homeless.
Properties listed as suitable/available
will be available exclusively for
homeless use for a period of 60 days
from the date of this Notice. Where
property is described as for ‘‘off-site use
only’’ recipients of the property will be
required to relocate the building to their
own site at their own expense.
Homeless assistance providers
interested in any such property should
send a written expression of interest to
HHS, addressed to Theresa Ritta, Office
of Enterprise Support Programs,
Program Support Center, HHS, room
12–07, 5600 Fishers Lane, Rockville,
MD 20857; (301) 443–2265. (This is not
a toll-free number.) HHS will mail to the
interested provider an application
packet, which will include instructions
for completing the application. In order
to maximize the opportunity to utilize a
suitable property, providers should
submit their written expressions of
interest as soon as possible. For
complete details concerning the
processing of applications, the reader is
encouraged to refer to the interim rule
governing this program, 24 CFR part
581.
For properties listed as suitable/to be
excess, that property may, if
subsequently accepted as excess by
GSA, be made available for use by the
homeless in accordance with applicable
law, subject to screening for other
Federal use. At the appropriate time,
HUD will publish the property in a
Notice showing it as either suitable/
available or suitable/unavailable.
For properties listed as suitable/
unavailable, the landholding agency has
decided that the property cannot be
declared excess or made available for
use to assist the homeless, and the
property will not be available.
Properties listed as unsuitable will
not be made available for any other
purpose for 20 days from the date of this
Notice. Homeless assistance providers
interested in a review by HUD of the
determination of unsuitability should
call the toll free information line at 1–
800–927–7588 for detailed instructions
or write a letter to Ann Marie Oliva at
the address listed at the beginning of
this Notice. Included in the request for
review should be the property address
(including zip code), the date of
publication in the Federal Register, the
PO 00000
Frm 00063
Fmt 4703
Sfmt 9990
59709
landholding agency, and the property
number.
For more information regarding
particular properties identified in this
Notice (i.e., acreage, floor plan, existing
sanitary facilities, exact street address),
providers should contact the
appropriate landholding agencies at the
following addresses: Army: Ms.
Veronica Rines, Office of the Assistant
Chief of Staff for Installation
Management, Department of Army,
Room 5A128, 600 Army Pentagon,
Washington, DC 20310, (571) 256–8145;
COE: Mr. Scott Whiteford, Army Corps
of Engineers, Real Estate, CEMP–CR,
441 G Street NW., Washington, DC
20314; (202) 761–5542; (These are not
toll-free numbers).
Dated: September 19, 2013.
Mark Johnston,
Deputy Assistant Secretary for Special Needs.
TITLE V, FEDERAL SURPLUS PROPERTY
PROGRAM FEDERAL REGISTER REPORT
FOR 09/27/2013
Suitable/Available Properties
Building
Arkansas
Beaver Reservoir Operational Facility
2256/2258 N. 2nd Street
Rogers AR 72756
Landholding Agency: COE
Property Number: 31201330006
Status: Unutilized
Directions: 2256 (1,750 sq. ft.); 2258 (1,430
sq. ft)
Comments: Off-site removal only; no future
agency use; residential; fair conditions;
contact COE for more info.
Unsuitable Properties
Building
Kentucky
875
Fort Campbell
Fort Campbell KY 42223
Landholding Agency: Army
Property Number: 21201330059
Status: Unutilized
Directions: Only building 875 has the 20-day
holding period from the Sept. 27 FR
Comments: Public access denied & no
alternative to gain access w/out
compromising nat’l security.
Reasons: Secured Area
[FR Doc. 2013–23341 Filed 9–26–13; 8:45 am]
BILLING CODE 4210–67–P
E:\FR\FM\27SEN1.SGM
27SEN1
Agencies
[Federal Register Volume 78, Number 188 (Friday, September 27, 2013)]
[Notices]
[Pages 59708-59709]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23528]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Commercialization License: The Use
of Cysteamine for the Treatment of Pancreatic Cancer, Breast Cancer and
Hepatocellular Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice, in accordance with 35 U.S.C. 209 and 37 CFR part
404, indicates that the National Institutes of Health, Department of
Health and Human Services, is contemplating the grant of an exclusive
commercialization license to practice the inventions embodied in
technology family E-219-2013/0, including U.S. patent application 61/
814,010 entitled ``A Novel Role of Cysteamine in Suppression of Cancer
Invasion and Metastasis and Prolonging Survival of Host Through
Inhibition of Matrix Metalloproteinases in Human Cancer'' [HHS Ref. E-
219-2013/0-US-01], Canadian patent application 2,813,514 entitled ``Use
of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases''
[HHS Ref. E-219-2013/0-CA-02], South Korean patent application 10-2013-
43713 entitled ``Use of Cysteamine and Derivatives Thereof to Suppress
Tumor Metastases''[HHS Ref. E-219-2013/0-KR-03], Australian patent
application 2013205350 entitled ``Use of Cysteamine and Derivatives
Thereof to Suppress Tumor Metastases'' [HHS Ref. E-219-2013/0-AU-04],
and Mexican patent application MX/a/2013/004423 entitled ``Use of
Cysteamine and Derivatives Thereof to Suppress Tumor Metastases'' [HHS
Ref. E-219-2013/0-MX-05]; and all related continuing and foreign
patents/patent applications for these technology families, to Raptor
Pharmaceuticals, Inc. The patent rights in these inventions have been
assigned to and/or exclusively licensed to the Government of the United
States of America.
The prospective exclusive commercialization license territory may
be worldwide, and the field of use may be limited to:
The treatment of pancreatic cancer, breast cancer and
hepatocellular carcinoma (HCC) by using compositions containing
cysteamine.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
October 28, 2013 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
commercialization license should be directed to: David A. Lambertson,
Ph.D., Senior Licensing and Patenting Manager, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4632;
Facsimile: (301) 402-0220; Email: lambertsond@mail.nih.gov.
SUPPLEMENTARY INFORMATION: Cysteamine is a naturally occurring
degradation product of the amino acid cysteine that is most commonly
used for the treatment of cystinosis. The inventors on this technology
have demonstrated that cysteamine suppresses the activity of matrix
metalloproteinases (MMPs), enzymes that have been implicated in tumor
invasion and metastasis. Importantly, administration of cysteamine was
able to reduce invasion and metastasis in mouse xenograft tumor models
for pancreatic cancer, prolonging the survival of the mice while having
no adverse side effects. Based on these findings, cysteamine could
represent a novel therapeutic treatment of cancer with fewer side-
effects than current therapies.
The prospective exclusive commercialization license will comply
with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The
prospective exclusive license may be granted unless the NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR part 404 within thirty (30) days from the date of this
published notice.
Complete applications for a license in the field of use filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive license. Comments and objections
[[Page 59709]]
submitted to this notice will not be made available for public
inspection and, to the extent permitted by law, will not be released
under the Freedom of Information Act, 5 U.S.C. 552.
Dated: September 20, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development & Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-23528 Filed 9-26-13; 8:45 am]
BILLING CODE 4140-01-P